Senior living provider The Pennant Group (NASDAQ: PNTG) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 37.3% year on year to $298 million. The company’s full-year revenue guidance of $1.18 billion at the midpoint came in 1.3% above analysts’ estimates. Its non-GAAP profit of $0.36 per share was 9.1% above analysts’ consensus estimates.

Is now the time to buy The Pennant Group? Find out by accessing our full research report, it’s free.

“Pennant delivered another strong quarter, putting us on pace to exceed the top end of our original full year guidance,” said Brent Guerisoli, the Company’s Chief Executive Officer.

Company Overview

Spun off from The Ensign Group in 2019 to focus on non-skilled nursing healthcare services, Pennant Group (NASDAQ: PNTG) operates home health, hospice, and senior living facilities across 13 western and midwestern states, serving patients of all ages including seniors.

Revenue Growth

A company’s long-term performance is an indicator of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Thankfully, The Pennant Group’s 22% annualized revenue growth over the last five years was excellent. Its growth beat the average healthcare company and shows its offerings resonate with customers.

Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. The Pennant Group’s annualized revenue growth of 35% over the last two years is above its five-year trend, suggesting its demand was strong and recently accelerated.

The Pennant Group also reports its number of admissions, which reached 28,947 in the latest quarter. Over the last two years, The Pennant Group’s admissions averaged 26.8% year-on-year growth. Because this number is lower than its revenue growth, we can see the company benefited from price increases.

This quarter, The Pennant Group reported wonderful year-on-year revenue growth of 37.3%, and its $298 million of revenue exceeded Wall Street’s estimates by 3.2%.

Looking ahead, sell-side analysts expect revenue to grow 10.4% over the next 12 months, a deceleration versus the last two years. Still, this projection is commendable and indicates the market is baking in success for its products and services.

ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.

Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.

Adjusted Operating Margin

Adjusted operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses — everything from the cost of goods sold to advertising and wages. It’s also useful for comparing profitability across companies because it excludes non-recurring expenses, interest on debt, and taxes.

The Pennant Group was profitable over the last five years but held back by its large cost base. Its average adjusted operating margin of 6.6% was weak for a healthcare business.

On the plus side, The Pennant Group’s adjusted operating margin rose by 2.4 percentage points over the last five years, as its sales growth gave it operating leverage.

This quarter, The Pennant Group generated an adjusted operating margin profit margin of 6.8%, in line with the same quarter last year. This indicates the company’s overall cost structure has been relatively stable.

Earnings Per Share

We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.

The Pennant Group’s EPS grew at an astounding 15.9% compounded annual growth rate over the last five years. Despite its adjusted operating margin improvement during that time, this performance was lower than its 22% annualized revenue growth, telling us that non-fundamental factors such as interest and taxes affected its ultimate earnings.

We can take a deeper look into The Pennant Group’s earnings quality to better understand the drivers of its performance. A five-year view shows The Pennant Group has diluted its shareholders, growing its share count by 17.3%. This dilution overshadowed its increased operational efficiency and has led to lower per share earnings. Taxes and interest expenses can also affect EPS but don’t tell us as much about a company’s fundamentals.

In Q2, The Pennant Group reported adjusted EPS of $0.36, up from $0.27 in the same quarter last year. This print beat analysts’ estimates by 9.1%. Over the next 12 months, Wall Street expects The Pennant Group’s full-year EPS to grow 10.6% from $1.32 to $1.46.

Key Takeaways from The Pennant Group’s Q2 Results

We enjoyed seeing The Pennant Group beat analysts’ revenue expectations this quarter. We were also glad its full-year revenue guidance slightly exceeded Wall Street’s estimates. Overall, we think this was a decent quarter with some key metrics above expectations. The stock remained flat at $38.55 immediately after reporting.

Is The Pennant Group an attractive investment opportunity right now? We think that the latest quarter is only one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here (it’s free).